The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 8th 2024
An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
RA Patients Still Have a "Considerable Need" for Treat-to-Target Care
November 27th 2019More than half of rheumatoid arthritis patients had persistent moderate-to-high disease activity after six months of treatment with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), and less than a third had their therapy escalated, indicating that there is considerable need for a treat-to-target approach to care for these patients, say researchers recently writing in Clinical Rheumatology.
Awkward but Important Patient Conversations: Problematic Drug and Alcohol Use
November 27th 2019This column will feature a series of focused overviews with practical suggestions for managing the manifold tricky needs of your patient population. This series started with a primer for addressing the sexual health questions of patients-paired with a healthy dose of required self-reflection (“Teach them to fish: Addressing the sexual health needs of patients and practice culture”). The series will continue with this dive into problematic substance use and next to coverage of other important but thorny issues including personality disorders, patient safety in the home (exposure to violence, abuse, or self-harm), cognitive impairment vis-à-vis medical decision-making, and the de-escalation of agitated, angry patients. There are other dozens of other difficult conversations, so please get in touch with suggestions.
Senior Rheumatoid Arthritis Patients May Be Missing Out on Treatments
November 22nd 2019Even though senior patients with rheumatoid arthritis receive biologic therapies less often than patients who develop the condition early in life, a Japanese study presented this month at the ACR annual meeting, shows that patients 60 years and older can benefit from therapy just as much as younger patients.
Study Shows Promise in Immunotherapy for Rheumatoid Arthritis
November 22nd 2019Researchers are exploring the possibility of using immune checkpoint inhibitors in rheumatoid arthritis patients. A small study presented at the American College of Rheumatology (ACR) annual meeting earlier this month shows that rheumatoid arthritis (RA) patients who were treated with immunotherapy, responded just as well as a comparable patient population with only 12 of 22 patients experiencing flares.
Trial Shows Switch from Etanercept Biologic to Biosimilar Maintains Clinical Outcomes
November 21st 2019A new study shows that the clinical status of patients who have either rheumatoid arthritis or axial spondyloarthritis, can be successfully maintained when switching from the biologic originator etanercept to a biosimilar called SB4.
Methotrexate Controls Joint Damage in Hand Osteoarthritis, Small Study Shows
November 18th 2019The first-ever study designed to assess the effectiveness of methotrexate on hand osteoarthritis finds that while the treatment did not demonstrate superior efficacy over placebo on pain or function, it did significantly reduce the progression of joint damage.
Ninfetanib Improves and Stabilizes Lung Function in Systemic Sclerosis
November 18th 2019Patients who have systemic sclerosis-associated interstitial lung disease and received nintedanib were more likely to have improved lung function than patients who received a placebo, according to a new study. Not only did nintedanib improve forced vital capacity, but patients who received the drug were less likely to experience declining clinical status and more likely to see their conditions stabilize.
RA Clinical Quiz: Should therapy be tapered?
November 18th 2019In today's installment of the rheumatoid arthritis clinical quiz, we examine treatment options for patients with established disease. Is sustained treatment with csDMARDs preferred over reducing the dose or dosing frequency of treatment? Click on the slideshow for more information.
One Step Closer for Macrophage Activation Syndrome Testing in Juvenile Arthritis
November 18th 2019Researchers reporting at the annual meeting of the American College of Rheumatology earlier this month say they have successfully identified a specific biomarker for macrophage activation syndrome, a complication of childhood rheumatic disease most often affecting children with systemic juvenile idiopathic arthritis.
ACR Annual Meeting Roundup: Higher death rates in lupus
November 14th 2019In today's slideshow, we highlight the best of the ACR Annual Meeting which wrapped this week in Atlanta. Among the highlights, includes a study that focuses on unusually high death rates in lupus, plus one that suggests new treatments for juvenile idiopathic arthritis are "urgently" needed. Learn more in this slideshow.
Q&A with Leonard Calabrese, DO: Vaccinating in Immunocompromised Patients
November 14th 2019Renowned infectious disease expert Leonard Calabrese, DO, professor of medicine at the Cleveland Clinic Lerner College of Medicine, takes part in a Q&A on vaccinations in immunocompromised patient populations.
Exposure to Industrial Air Pollutants Linked to Rheumatoid Arthritis Biomarker
November 13th 2019ACR Annual Meeting: Exposure to industrial emissions of fine particles matter and sulfur dioxide are associated with the presence of anti-citrullinated protein antibodies, a characteristic biomarker for rheumatoid arthritis, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
Anifrolumab Shows Efficiency in Systemic Lupus
November 13th 2019ACR Annual Meeting: In patients with moderate to severe systemic lupus erythematosus, anifrolumab (AstraZeneca) was superior to placebo for overall disease activity, skin disease and oral corticosteroid tapering, among other efficacy endpoints, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
Conventional Therapy Bests Tapered Therapy in Rheumatoid Arthritis
November 13th 2019In rheumatoid arthritis patients who are in sustained remission and receiving conventional synthetic DMARDs, continued treatment with stable doses led to fewer disease activity flares and less frequent radiographic joint damage progression than tapered csDMARD treatment, shows a study.
Philip Mease, MD: The Role of JAK Inhibitors in Psoriatic Arthritis
November 13th 2019Philip Mease, MD, Director of Rheumatology Research at the Swedish Rheumatology Research Group, discusses why he believes some rheumatologists are skeptical of JAK inhibitors and where they fit in current treatment algorithms.